Pharmaceutical

ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight

As the stage is set for another year of groundbreaking research and transformative treatment advancements, several companies are seizing the…

4 months ago

Cellares and Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting and Online Analysis into an Automated, High-Throughput Cell Therapy Manufacturing Platform

Cellares and Sony will collaborate on integrating Sony's cell sorting and analytical technologies into the Cell Shuttle, Cellares' automated cell…

4 months ago

PhaseV Unveils Machine Learning-Powered Platform to Improve Oncology Clinical Trials

Company Leverages Causal Machine Learning to Overcome Key Challenges in Developing New Cancer Treatments BOSTON, Sept. 12, 2024 /PRNewswire/ --…

4 months ago

Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer

CAMBRIDGE, England, Sept. 12, 2024 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring…

4 months ago

Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion App to aid in the treatment of Parkinson’s Disease

STOCKHOLM, Sept. 12, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to…

4 months ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

4 months ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…

4 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all…

4 months ago

Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)

PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating…

4 months ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

$10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:…

4 months ago